FORA Capital’s Castle Biosciences CSTL Stock Holding History

FORA Capital’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-416	Closed	-$31K	–	471
2021 Q2	$31K	Sell	416 -954	-70%	-$63K	0.01%	777
2021 Q1	$94K	Sell	1,370 -7,930	-85%	-$596K	0.03%	423
2020 Q4	$624K	Buy	9,300 +8,834	+1,896%	+$479K	0.1%	239
2020 Q3	$24K	Buy	+466	New	+$20.7K	0.02%	555

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

ZCI

Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return

FORA Capital's CSTL Position: Q3 2021 in Review

FORA Capital sold out of Castle Biosciences (CSTL) in Q3 2021, closing a stake of 416 shares — an estimated $31K sold.

FORA Capital first reported a position in CSTL in Q3 2020 and held it in 4 quarters. The position peaked at $624K in Q4 2020. 188 funds tracked by Wall St. Rank hold CSTL as of Q3 2021.

FORA Capital reported no remaining Castle Biosciences position as of Q3 2021 after selling out during the quarter.
FORA Capital sold 416 Castle Biosciences shares in Q3 2021, an estimated $31K.
FORA Capital first reported a position in Castle Biosciences in Q3 2020 and held it in 4 quarters.
FORA Capital's Castle Biosciences position peaked at $624K in Q4 2020.
188 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2021.

Based on FORA Capital's 13F filing for Q3 2021, filed 15 Nov 2021.